What sponsor side actually pays, function by function

The received wisdom is simple: leave the CRO, join a sponsor, get paid more and travel less. Like most received wisdom about pay, it is half right and untestable with the numbers most people have. Here is what the public record actually supports, function by function, and where the "sponsors pay more" story holds and breaks.

Where the premium is real

For the functions that sit closest to the molecule and the submission, sponsor side generally does pay a premium, and the filings support it. Biostatistics is the clearest case. On our salaries page, CRO senior biostatisticians filed in the low $130,000s ($132,964 and $136,644 in recent records), while advertised sponsor-dedicated (FSP) senior biostatistician ranges reached as high as $233,400 at the top. The top of that advertised band is a recruiting ceiling, not a typical offer, but the direction is real: specialized, submission-critical roles command more where the drug's value is highest, which is the sponsor.

Where it is a wash

For monitoring, the premium is thinner than the folklore suggests. Sponsors run leaner clinical operations teams and outsource most monitoring to CROs, so a sponsor CRA role is rarer and often more senior by the time it exists. The base may be similar to a senior CRO CRA in the low $120,000s. What changes is rarely the number on the offer letter. It is the calendar, the metrics pressure, and the benefits, which is a different kind of raise.

What the offer letter hides

The sponsor-side advantage that does not show up in a base-salary comparison is total compensation structure. Large pharma tends to carry richer bonus targets, real equity, and stronger benefits than a CRO, whose margins are thinner by the nature of the business. A sponsor base that matches your CRO base can still be a meaningful raise once bonus and equity land. The reverse trap: a CRO counteroffer that beats a sponsor base can still be worse in total.

This is why comparing sponsor and CRO offers on base alone is a mistake. The comparison that matters is base plus bonus plus equity plus the cash value of the benefits and the travel policy. We walk through that math in the CRO-versus-sponsor piece; the short version is that the base is often the least important line.

The honest gap

Here is what no public source can give you: sponsor-side pay by function is thinly documented because sponsors sponsor fewer visas per role than CROs do, so the government-filing well is shallower for pharma than for the big CROs. Sponsor comp is real, but it hides inside private pay bands and total-comp packages that never reach a public filing. The people who know the real sponsor numbers are the people holding sponsor offers right now.

If that is you, or was recently, your datapoint is the rarest and most valuable kind this survey collects. The CRO side is comparatively well-lit by filings. The sponsor side is where the community can see something the government record cannot show. Add yours.